Erik Richardson

Erik Richardson possesses extensive experience in clinical and translational development within the biotechnology sector, currently serving as Director and Program Lead at Apellis Pharmaceuticals since July 2019. Prior roles at Acucela Inc. included Project Leader for a gene therapy program, where Erik led the development of an adeno-associated virus (AAV) optogenetic gene therapy for Retinitis Pigmentosa. Erik’s earlier experience encompasses technology analysis at BioWatch News, focusing on biotechnology trends, and a leadership role in the founding of a student business club at the University of Washington dedicated to healthcare. Erik holds a Bachelor of Science in Biochemistry and a Bachelor of Business Administration in Operations and Supply Chain Management from the University of Washington.